Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › clopidogrel

clopidogrel

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of clopidogrel

80 trials tracked of clopidogrel: 49 in phase 3 or 4 and 18 with published results. The most-cited published study has 1502 citations.

80Trials tracked
49Phase 3 & 4
0Recruiting
18With published results
Phase distribution
Phase 4 32 Phase 3 17 Phase 2 18 Phase 1 9 Other / NA 4
  1. Phase 4 Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study) Completed · 1,502 cited
  2. Phase 3 Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Completed · 658 cited
  3. Phase 4 Tailored Antiplatelet Therapy Following PCI Completed · 402 cited
  4. Phase 3 Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) Completed · 280 cited
  5. Phase 4 Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial Completed · 82 cited
  6. Phase 3 A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention Completed · 74 cited
Show 44 more trials
  1. Phase 4 Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease Completed · 56 cited
  2. Phase 4 STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction Completed · 53 cited
  3. Phase 3 GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation Completed · 50 cited
  4. Phase 4 Ranitidin Versus Omeprazole in Patients Taking Clopidogrel Completed · 26 cited
  5. Phase 4 Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus Completed · 19 cited
  6. Phase 4 Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI Completed · 14 cited
  7. Phase 3 A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease Completed · 13 cited
  8. Phase 4 Clopidogrel and Aspirin Interaction Study-2 Completed · 11 cited
  9. Phase 4 Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Completed · 10 cited
  10. Phase 3 STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction Completed · 7 cited
  11. Phase 4 Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus Completed · 3 cited
  12. Phase 4 Clopidogrel Monotherapy in Patients With High Bleeding Risk Completed · 1 cited
  13. Phase 4 Pharmacogenomics of Antiplatelet Response - I Completed
  14. Phase 4 Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation Completed
  15. Phase 4 Clopidogrel Versus Ticagrelor in Type-2 Diabetes Completed
  16. Phase 4 Antiplatelet Therapy After Cardiac Arrest Completed
  17. Phase 4 P3AMI Antiplatelet Trial Completed
  18. Phase 4 Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction Completed
  19. Phase 4 Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI Completed
  20. Phase 4 Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR) Completed
  21. Phase 4 CES1 Carriers in the PAPI Study Completed
  22. Phase 4 CES1 Crossover Trial of Clopidogrel and Ticagrelor Completed
  23. Phase 4 Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II Completed
  24. Phase 4 PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes Completed
  25. Phase 4 Investigation of the Athero-Protective Effects of Clopidogrel Completed
  26. Phase 4 Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study) Completed
  27. Phase 4 A Pharmacodynamic Study With Ticagrelor in Hispanic Patients Completed
  28. Phase 4 Prasugrel/Clopidogrel Maintenance Dose Washout Study Completed
  29. Phase 4 A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS Completed
  30. Phase 4 A Pharmacodynamic Study With Ticagrelor in African American Patients Completed
  31. Phase 4 The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease Completed
  32. Phase 4 Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients Completed
  33. Phase 3 Efficacy and Safety of Low-dose Ticagrelor Completed
  34. Phase 3 Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities Completed
  35. Phase 3 Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation Completed
  36. Phase 3 A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome Completed
  37. Phase 3 Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS Completed
  38. Phase 3 Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) Completed
  39. Phase 3 Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry Completed
  40. Phase 3 A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention Completed
  41. Phase 3 Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events Completed
  42. Phase 3 A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome Completed
  43. Phase 3 A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects Completed
  44. Phase 2 Cangrelor to Clopidogrel or Prasugrel Transition Study Completed

Showing the 50 most-cited and recently-updated of 80 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Post hoc analysis finds cilostazol reduces stroke recurrence without lowering systolic blood pressure
Neurology RCT
Post hoc analysis finds cilostazol reduces stroke recurrence without lowering systolic blood pressure Study finds cilostazol reduces stroke recurrence without lowering blood pressure
A post hoc mediation analysis of an RCT in 1,795 patients with noncardioembolic ischemic stroke found dual therapy with cilostazol plus…
Cilostazol lowers stroke recurrence risk in patients with prior noncardioembolic strokes without working by dropping their blood pressure.
Apr 3, 2026